A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Confidential
Rambam Hospital
Haifa, Israel
Shalvata Mental Health Center (SMHC)
Hod HaSharon, Israel
Safety & Tolerability Evaluation
Safety and tolerability of ND0801 will be based on adverse events reporting by the subjects during the study.
Time frame: 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.